---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-056294"
form_type: "8-K"
ticker: "PMVP"
cik: "0001699382"
company_name: "PMV Pharmaceuticals, Inc."
filed_at: "2024-05-09T23:59:59+00:00"
generated_at: "2026-06-02T06:26:27.725602+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# PMV Pharma Q1 loss narrows to $15.3M; Phase 2 PYNNACLE trial initiated

## Summary
- Net loss $15.3M vs $19.1M YoY; cash $213.1M, expected runway to end of 2026.
- First patient dosed in registrational Phase 2 PYNNACLE trial for rezatapopt (TP53 Y220C/KRAS wild-type).
- Phase 1 ovarian cancer data: 7/15 confirmed partial responses, median duration 7 months.
- R&D expenses $13.2M (down from $15.1M); G&A $5.0M (down from $6.4M).
- Net cash used in operations $16.2M vs $15.0M in Q1 2023.

## SEC filing metadata
- accession: 0000950170-24-056294
- form_type: 8-K
- ticker: PMVP
- cik: 0001699382
- company_name: PMV Pharmaceuticals, Inc.
- filed_at: 2024-05-09T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1699382/000095017024056294/0000950170-24-056294-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1699382/000095017024056294/pmvp-20240509.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-056294
- JSON: https://secwatch.observer/filing/0000950170-24-056294.json
- Plain text: https://secwatch.observer/filing/0000950170-24-056294.txt

## Key facts
- Earnings Releases
  PMV Pharmaceuticals, Inc. reported the first quarter ended March 31, 2024 results: net income Net loss for the quarter ended March 31, 2024, was $15.3 million.
  - Period: the first quarter ended March 31, 2024
  - Net income: Net loss for the quarter ended March 31, 2024, was $15.3 million
  - Result: reported results
  source text: PMV Pharmaceuticals, Inc. issued a press release announcing its financial results for the first quarter ended March 31, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1699382/000095017024056294/0000950170-24-056294-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.